Metabolite profiling stratifies pancreatic ductal adenocarcinomas into subtypes with distinct sensitivities to metabolic inhibitors

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 32, 2015, Pages E4410-E4417

  Daemen, Anneleen ^a   Peterson, David ^a   Sahu, Nisebita ^a   McCord, Ron ^a   Du, Xiangnan ^a   Liu, Bonnie ^a   Kowanetz, Katarzyna ^a   Hong, Rebecca ^a   Moffat, John ^a   Gao, Min ^a   Boudreau, Aaron ^a   Mroue, Rana ^a   Corson, Laura ^a   O'Brien, Thomas ^a   Qing, Jing ^a   Sampath, Deepak ^a   Merchant, Mark ^a   Yauch, Robert ^a   Manning, Gerard ^a   Settleman, Jeffrey ^a   Hatzivassiliou, Georgia ^a   Evangelista, Marie ^a   DePinho, Ronald A ^b   more..

^a GENENTECH INC   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Biomarkers for metabolic inhibitors; Glycolysis; Lipid synthesis; Metabolic subtypes in PDAC; Metabolite profiling

Indexed keywords

GLUCOSE; GLUTAMINE; TUMOR MARKER;

ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; DISEASE COURSE; DRUG RESPONSE; GENOMICS; GLYCOLYSIS; IN VITRO STUDY; IN VIVO STUDY; LIPID METABOLISM; LIPOGENESIS; MESENCHYME CELL; METABOLITE; NONHUMAN; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; ADENOCARCINOMA; CLASSIFICATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; IC50; MESODERM; METABOLISM; METABOLOME; METABOLOMICS; PANCREAS CARCINOMA; PATHOLOGY; REPRODUCIBILITY;

ADENOCARCINOMA; BIOMARKERS, TUMOR; CARCINOMA, PANCREATIC DUCTAL; CELL PROLIFERATION; GLUCOSE; GLUTAMINE; GLYCOLYSIS; HUMANS; INHIBITORY CONCENTRATION 50; LIPOGENESIS; MESODERM; METABOLOME; METABOLOMICS; REPRODUCIBILITY OF RESULTS; TRANSCRIPTION, GENETIC;

EID: 84938940583     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1501605112     Document Type: Article

References (59)

1. Warburg O, Posener K, Negelein E (1924) On the metabolism of carcinoma cells. Biochem Z 152:309-344.
2. Dang L, et al. (2009) Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462(7274):739-744.
3. Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB (2008) Brick by brick: Metabolism and tumor cell growth. Curr Opin Genet Dev 18(1):54-61.
4. Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond. Cell 134(5): 703-707.
5. Anastasiou D, et al. (2012) Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol 8(10):839-847.
6. Le A, et al. (2012) Glucose-independent glutamine metabolism via TCA cycling for proliferation and survival in B cells. Cell Metab 15(1):110-121.
7. Xie H, et al. (2014) Targeting lactate dehydrogenase-a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. Cell Metab 19(5):795-809.
8. Available at www.clinicaltrials.gov. Accessed December, 2014.
9. Jain M, et al. (2012) Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 336(6084):1040-1044.
10. Sreekumar A, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457(7231):910-914.
11. Hu J, et al. (2013) Heterogeneity of tumor-induced gene expression changes in the human metabolic network. Nat Biotechnol 31(6):522-529.
12. Dang CV (2010) Glutaminolysis: Supplying carbon or nitrogen or both for cancer cells? Cell Cycle 9(19):3884-3886.
13. Barretina J, et al. (2012) The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603-607.
14. Garnett MJ, et al. (2012) Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 483(7391):570-575.
15. Ying H, et al. (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149(3):656-670.
16. Son J, et al. (2013) Glutamine supports pancreatic cancer growth through a KRASregulated metabolic pathway. Nature 496(7443):101-105.
17. Zhang G, et al. (2013) Integration of metabolomics and transcriptomics revealed a fatty acid network exerting growth inhibitory effects in human pancreatic cancer. Clin Cancer Res 19(18):4983-4993.
18. Commisso C, et al. (2013) Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature 497(7451):633-637.
19. McDermott U, et al. (2007) Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 104(50):19936-19941.
20. Heiser LM, et al. (2012) Subtype and pathway specific responses to anticancer compounds in breast cancer. Proc Natl Acad Sci USA 109(8):2724-2729.
21. Brunet JP, Tamayo P, Golub TR, Mesirov JP (2004) Metagenes and molecular pattern discovery using matrix factorization. Proc Natl Acad Sci USA 101(12):4164-4169.
22. Collisson EA, et al. (2011) Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med 17(4):500-503.
23. Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490(7418):61-70.
24. Cancer Genome Atlas Research Network (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513(7517):202-209.
25. Mutch DM, et al. (2009) Metabolite profiling identifies candidate markers reflecting the clinical adaptations associated with Roux-en-Y gastric bypass surgery. PLoS One 4(11):e7905.
26. O'Brien T, et al. (2014) Abstract 964: Inhibiting glycolysis with an LDHA inhibitor: A new solution to an old problem. Cancer Res 74(19, Suppl):964.
27. Chaudhari AM, Hallman J, Laudeman CP, Musso DL, Parrish CA (2011) Azabenzimidazoles as fatty acid synthase inhibitors and their preparation and use for the treatment of cancer. US Patent WO 2011066211 A1 (June 3, 2011).
28. Du X, et al. (2012) FGFR3 stimulates stearoyl CoA desaturase 1 activity to promote bladder tumor growth. Cancer Res 72(22):5843-5855.
29. Acharya A, Das I, Chandhok D, Saha T (2010) Redox regulation in cancer: A doubleedged sword with therapeutic potential. Oxid Med Cell Longev 3(1):23-34.
30. Ashkenazi A, Du X, Qing J (2013) Methods of using scd1 antagonists. US Patent WO2013056148 A2 (April 18, 2013).
31. Thiery JP, Acloque H, Huang RY, Nieto MA (2009) Epithelial-mesenchymal transitions in development and disease. Cell 139(5):871-890.
32. Peinado H, Olmeda D, Cano A (2007) Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer 7(6):415-428.
33. Cheng WY, Ou Yang TH, Anastassiou D (2013) Development of a prognostic model for breast cancer survival in an open challenge environment. Sci Transl Med 5(181): 181ra50.
34. Hitosugi T, et al. (2012) Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth. Cancer Cell 22(5):585-600.
35. Muller FL, et al. (2012) Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488(7411):337-342.
36. Gorrini C, Harris IS, Mak TW (2013) Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov 12(12):931-947.
37. Yauch RL, et al. (2005) Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 11(24 Pt 1):8686-8698.
38. Lomakin IB, Steitz TA (2013) The initiation of mammalian protein synthesis and mRNA scanning mechanism. Nature 500(7462):307-311.
39. Gingras AC, Raught B, Sonenberg N (2001) Regulation of translation initiation by FRAP/mTOR. Genes Dev 15(7):807-826.
40. Luyimbazi D, et al. (2010) Rapamycin regulates stearoyl CoA desaturase 1 expression in breast cancer. Mol Cancer Ther 9(10):2770-2784.
41. Menendez JA, Lupu R (2007) Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 7(10):763-777.
42. Kim JW, Gao P, Liu YC, Semenza GL, Dang CV (2007) Hypoxia-inducible factor 1 and dysregulated c-Myc cooperatively induce vascular endothelial growth factor and metabolic switches hexokinase 2 and pyruvate dehydrogenase kinase 1. Mol Cell Biol 27(21):7381-7393.
43. Yoo YG, Christensen J, Huang LE (2011) HIF-1α confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function. Cancer Res 71(4):1244-1252.
44. van Ravenzwaay B, et al. (2007) The use of metabolomics for the discovery of new biomarkers of effect. Toxicol Lett 172(1-2):21-28.
45. Shukla K, et al. (2012) Design, synthesis, and pharmacological evaluation of bis-2-(5- phenylacetamido-1, 2, 4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors. J Med Chem 55(23):10551-10563.
46. R Development Core Team (2009) R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna).
47. Jiang Z, Gentleman R (2007) Extensions to gene set enrichment. Bioinformatics 23(3): 306-313.
48. Gaujoux R, Seoighe C (2010) A flexible R package for nonnegative matrix factorization. BMC Bioinformatics 11:367.
49. Kim PM, Tidor B (2003) Subsystem identification through dimensionality reduction of large-scale gene expression data. Genome Res 13(7):1706-1718.
50. Wu TD, Nacu S (2010) Fast and SNP-tolerant detection of complex variants and splicing in short reads. Bioinformatics 26(7):873-881.
51. Klijn C, et al. (2015) A comprehensive transcriptional portrait of human cancer cell lines. Nat Biotechnol 33(3):306-312.
52. Possemato R, et al. (2011) Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature 476(7360):346-350.
53. Mootha VK, et al. (2003) PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 34(3): 267-273.
54. McCleland ML, et al. (2013) Lactate dehydrogenase B is required for the growth of KRAS-dependent lung adenocarcinomas. Clin Cancer Res 19(4):773-784.
55. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102(43):15545-15550.
56. Cheng WY, Ou Yang TH, Anastassiou D (2013) Biomolecular events in cancer revealed by attractor metagenes. PLOS Comput Biol 9(2):e1002920.
57. Gray DC, et al. (2007) pHUSH: A single vector system for conditional gene expression. BMC Biotechnol 7:61.
58. Pinheiro J, Bates D, DebRoy S, Sarkar D, R Development Core Team (2009) nlme: Linear and nonlinear mixed effects models. R Package Version 3.1-96. Available at CRAN.R-project.org/package=nlme. Accessed July 8, 2015.
59. Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 57(1):289-300.